Abbott assumed with a Buy at UBS

UBS analyst Danielle Antalffy assumed coverage of Abbott with a Buy rating and $117 price target as part of a sector note on U.S. Medical Supplies and Devices. UBS believes Abbott’s ability to sustain above-market Medical Devices growth and top-tier high-single-digit total company sales growth is underappreciated, and sees Abbott’s recent and upcoming product launches as offering a plethora of shots on goal to sustain its recent positive momentum within Medical Devices, the analyst tells investors in a research note.